安斯泰来制药:FDA根据《处方药使用者费用法案》设定2026年8月17日为关键审批日期

美股速递
Apr 20

根据《处方药使用者费用法案》框架,美国食品药品监督管理局已为安斯泰来制药的核心新药申请划定重要时间节点——2026年8月17日被正式确立为监管审评的目标行动日期。这一关键时间点的设定,标志着该创新疗法的审评进程进入倒计时阶段,为市场预期提供了明确的时间坐标。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10